Age at IgG4-RD diagnosis years | 26 | 36 | 54 | 70 | 48 |
Sex | Female | Female | Female | Female | Female |
Classification of PAH | Idiopathic | Idiopathic | Idiopathic | Heritable | Idiopathic |
Interval between diagnoses of PAH and IgG4-RD months | 78 | 69 | 65 | 125 | 82 |
Organ involvement of IgG4-RD | Lacrimal and salivary glands, pancreas | Lacrimal and salivary glands | Lacrimal and salivary glands | Lacrimal and salivary glands | Lacrimal and salivary glands, pancreas |
Serum IgG4 level at diagnosis of IgG4-RD mg·dL−1 | 824 | 1190 | 896 | 2220 | 92 |
Concomitant allergic disease | Chronic sinusitis | Bronchial asthma | None | Chronic sinusitis | Chronic sinusitis |
PAH drugs at IgG4-RD diagnosis | Epoprostenol | Epoprostenol, bosentan | Epoprostenol, sildenafil | Epoprostenol, bosentan, sildenafil | Epoprostenol, bosentan, sildenafil |
Duration of epoprostenol treatment at IgG4-RD diagnosis months | 61 | 60 | 65 | 54 | 79 |
Maximum dose of epoprostenol ng·kg−1·min−1 | 85 | 33 | 57 | 53 | 93 |
Accumulated lifetime dose of epoprostenol mg·kg−1 | 73 | 71 | 78 | 64 | 96 |